13G Filing: Barrett Ehrlich and Oncbiomune Pharmaceuticals, Inc (OBMP)

Page 4 of 6 SEC Filing

CUSIP No. 68235A101   13G/A   Page 4 of 6 Pages

Item 1.

  (a) Name of Issuer
ONCBIOMUNE
PHARMACEUTICALS, INC.
 
  (b) Address of Issuer’s Principal Executive Offices
330
Clematis Street, Suite 217, West Palm Beach, Florida 33401
 

Item 2.

  (a) Name of Person Filing
THE BARRETT EDGE INC.
BARRETT EHRLICH
 
  (b) Address of the Principal Office or, if none, residence
260 MADISON AVE. NEW YORK, NY 10016
 
  (c) Citizenship
THE BARRETT EDGE INC. IS A NEW YORK CORPORATION
BARRETT
EHRLICH IS A UNITED STATES CITIZEN
 
  (d) Title of Class of Securities
COMMON
 
  (e) CUSIP Number
68235A101
 

Item 3.  If this
statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

  (a) Broker or dealer registered under section 15 of
the Act (15 U.S.C. 78o).
 
  (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
 
  (c) Insurance company as defined in section 3(a)(19) of the Act
(15 U.S.C. 78c).
 
  (d) Investment company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C. 80a-8).
 
  (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
 
  (f) An employee benefit plan or endowment fund in accordance with
§240.13d-1(b)(1)(ii)(F);
 
  (g) A parent holding company or control person in accordance with
§240.13d-1(b)(1)(ii)(G);
 
  (h) A savings associations as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);
 
  (i) A church plan that is excluded from the definition of an investment
company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 
  (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).
 

Follow Theralink Technologies Inc. (OTCMKTS:THER)